Sponsor Pipeline

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
1
Recruiting
1
Phase 3
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-21 NCT07716917 Genitourinary Tumors With Sacituzumab Tirumotecan Phase 2 Not Yet Recruiting
2026-07-21 NCT07717099 Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 3
1
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07333066 Phase III Randomized International Open Label Clinical Trial of Treatment Intensification… Metastatic Hormone-sensitive Prostate Cancer Recruiting
Phase 2
NCT07717099 Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Metastatic Hormone-Sensitive Prostate Cance Not Yet Recruiting
NCT07716917 Genitourinary Tumors With Sacituzumab Tirumotecan Papillary Renal Carcinoma Not Yet Recruiting
Disease Areas
Prostate Cancer (1) Bladder Cancer (1)
Get alerts when Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free